A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract
Key facts
- Who runs it
- Helwan University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 83 people enrolled
- Started
- 10 Jan 2023
- Ended
- 15 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fermented Deglycyrrhizinated Licorice
- Non-fermented Deglycyrrhizinated Licorice
- Record updated
- 29 August 2025
Who can take part
- Age
- 15 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Confirmed diagnosis of Type 1 or Type 2 diabetes mellitus
- Age between 15 and 65 years
- Diabetes duration of 1-5 years
- Body Mass Index (BMI) < 30 kg/m²
- HbA1c < 9%
- Serum creatinine < 2mg/dL
- Serum α-amylase < 45 IU/L (reference range: 28-100 IU/L)
- Vibration Perception Threshold (VPT) > 15V
- Absence of clinical symptoms of diabetic polyneuropathy
Who cannot take part
- Treatment with medications that might influence nerve function (antiepileptic agents, tricyclic antidepressants, sympathomimetic agents)
- Presence of malignancies
- Presence of myopathies
- Presence of neuropathies from other causes
- Clinical symptoms of diabetic polyneuropathy
- Inability to comply with study protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This double-blind, placebo-controlled study evaluated the efficacy of oral α-amylase enzyme replacement therapy in treating early-stage diabetic polyneuropathy (DPN). The study was conducted at Al-Azhar University Hospitals with 83 diabetic patients randomized to receive either fermented deglycyrrhizinated licorice extract (FDGL) containing α-amylase enzyme (2500 IU/gm) or placebo for 6 months. Primary outcomes measured improvements in nerve conduction velocity and vibration perception threshold.
The 2 groups in the trial
- Fermented Deglycyrrhizinated LicoriceExisting treatment, for comparison
Oral capsules containing 500 mg of fermented deglycyrrhizinated licorice root extract standardized to 2500 IU/gm of α-amylase enzyme and naturally occurring flavonoids and acid-lipase. Administered twice daily (1000 mg/day).
- Placebo ComparatorPlacebo, for comparison
500 mg non-fermented deglycyrrhizinated licorice root extract capsules, matching FDGL in appearance, color, weight, and excipients. Administered twice daily.
Treatment: Non-fermented Deglycyrrhizinated Licorice
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Oral α-Amylase Enzyme Replacement for the Treatment of Diabetic Polyneuropathy
- Publications
- Record updated
- 29 August 2025